RNA Outsourcing Videos
-
Mitigating Financial Risk Before Selecting An Outsourcing Vendor
9/25/2023
Gain insight from several clinical operations experts into the significance of meticulous contract examination when choosing an outsourcing partner.
-
How To Bring Your LNP Formulation To Clinical/Commercial Manufacturing
5/23/2024
Gain valuable insights into key considerations when selecting lipid excipients for LNP formulations and the process development steps necessary to advance them to GMP manufacturing and clinical trials.
-
How Can Sponsors & CDMOs Collaborate On RNA Analytical/Process Development?
8/22/2024
Having worked on both the innovator and CDMO sides of the industry, Advancing RNA LIVE panelist Khaled Yamout outlines where he sees the greatest weaknesses in these critical sponsor-CDMO partnerships and offers guidance.
-
An Early Formulation Screening Service
5/23/2024
Gain insights into overcoming the challenges in lipid nanoparticle (LNP) formulation, explore critical aspects of the process and analytical development of LNPs, and much more.
-
Scale-Up And Production Of Key Lipids Used In mRNA Delivery Systems
2/13/2025
Discover key strategies for overcoming challenges in the industrial-scale production of ionizable and PEG lipids to optimize mRNA vaccine formulation and address critical manufacturing requirements.
-
mRNA's Impact On Cost And Capacity To Surge Biopharma Production
5/22/2023
TFF Pharmaceuticals’ Kayla Hannon and University of Sheffield’s Dr. Zoltán Kis discuss the cost and capacity implications of therapeutic demand surges in this Surge Manufacturing for Biopharma Resilience segment.
-
Intelligent Manufacturing Of mRNA Through The Power Of Process Analytical Technologies
3/10/2025
Learn how predictive models can monitor key CQAs, such as RNA concentration and nucleoside triphosphate consumption, and explore RBP and MIT’s vision for revolutionizing biomanufacturing.
-
Face- Phase-Off: Matching CDMO Capabilities To Your mRNA-LNP Development Stage
2/10/2025
There are many different criteria for selecting a CDMO for your mRNA products. Arcturus’ Qian Ruan explains that a product’s stage of development and the specific needs inherent to that phase of development should be an important guide for companies today, especially given the expansion of the outsourcing sector and the wide range of capabilities.
-
How A Sponsored CMC Platform Accelerates mRNA Projects Into The Clinic
1/31/2023
Developing a client-sponsored Target Product Profile (TPP) and Analytical Target Profile (ATP) is critical to move your drug product to clinic efficiently and meet acceptance criteria.
-
Mastering The Complexities Of Gene Therapy Document Writing
5/20/2025
Gain the insight and strategic flexibility needed to confidently navigate the unique scientific, regulatory, and documentation challenges of gene therapy development.